Forty Seven, Inc.

Forty Seven, Inc.

Forty Seven, Inc.

Date Founded



1490 O'Brien Drive,Suite A,Menlo Park, CA 94025

Type of Company


Employees (Worldwide)



Hospitals & Patient Services
Medical Support Services

Company Description

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Contact Data
Trying to get in touch with decision makers at Forty Seven, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees


President & Chief Executive Officer

Chief Financial Officer

Chief Business Officer

Chief Medical Officer

Chief Patent Counsel

Senior Vice President Planning & Operations

Vice President Technical Development & Manufacturing

Founder & Vice President Research & Early Development


Board of Directors

Non-Resident Fellow at The Salk Institute for Biological Studies

Managing Director at Sutter Hill Ventures LLC

Operating Partner at Clarus Ventures LLC

President & Chief Executive Officer at Forty Seven, Inc.

Chief Scientific Advisor at Clarus Ventures LLC

Associate Professor at Stanford University

Senior Vice President of Corporate Strategy & Chief Financial Officer at Menlo Therapeutics, Inc.

Paths to Forty Seven, Inc.
Potential Connections via
Relationship Science
Forty Seven, Inc.
Owners & Shareholders
Details Hidden

Stanford Management Co. manages the majority of the Stanford University's endowment assets through the Merged Endowment Pool (MEP), which is a diversified portfolio of actively managed financial and real estate assets. SMC, with assistance from its board, actively manages the endowment, while remaining committed to a consistent long-term investment strategy. The MEP portfolio is constructed on a foundation of modern portfolio theory and strategic asset allocation and is tested through the rigors of state-of-the-art risk management techniques. The portfolio is designed to optimize long-term returns, create consistent annual payout to the University's operating budget and preserve purchasing power for future generations of Stanford faculty and students.The Absolute Return portfolio is constructed to provide returns that are substantially uncorrelated to the equity and bond markets. The portfolio includes quantitative and fundamental equity hedge fund strategies, emerging markets, distressed debt, fixed income relative value and multi-strategy arbitrage funds.Driven by appreciating commodity prices, the Natural Resources portfolio holds a diverse portfolio of managers in the oil, gas, energy and timber industries.Stanford's endowment historically has had a substantial commitment to Real Estate. The strategy of overweighting real estate investments is based on SMC's experience in real estate development and management of University lands. The portfolio includes direct investments in commercial and residential real estate development, limited partnership positions in real estate opportunity funds and publicly traded REITs. SMC prefers to invest in real estate assets outside of the San Francisco Bay Area and Santa Clara County to provide economic diversification and seismic risk mitigation. The MEP's global Real Estate portfolio creates returns through value-added activities and the demand for well-positioned assets.

Details Hidden

Sectoral Asset Management specializes in managing global portfolios that invest in the healthcare sector. The firm employs a bottom-up investment approach that can be categorized as growth at a reasonable price (GARP). Investments are selected using a focused stock selection process based on primary research of company fundamentals and close contacts with company management to assess their scientific, business and financial aspects. Specific areas of interest include: Health Care Equipment & Supplies, Health Care Providers & Services, Health Care Technology, Biotechnology, Pharmaceuticals and Life Sciences Tools & Services.

Details Hidden

Bourgeon Capital Management's (BCM) investment strategy includes the objective of a broad degree of issuer diversification. In general, the firm invests their clients' assets primarily in publicly-traded securities and shares of mutual funds and ETFs. The securities held in client accounts include, among other things,exchange-listed securities, securities traded over the counter, securities of foreign issuers, common stock, preferred stock, warrants, corporate debt securities, commercial paper, certificates of deposit, municipal securities, shares of mutual funds and ETFs, US government securities, options contracts on securities, futures contracts on tangibles and intangibles, partnership interests, and limited liability company interests. Most managed accounts have a cash component.BCM also serves as the investment advisor to Bourgeon Partners LP, a fundamental long-short pooled investment vehicle that invests primarily in publicly-traded equity securities issued by US companies. The fund focuses primarily on well-known large- and mid-cap companies. BCM defines large- cap companies as those with market capitalizations of more than $5 billion and mid-cap companies as those with market capitalizations of $1 billion to $5 billion. BCM places special emphasis on identifying out-of-favor companies which they feel are mispriced.

Recent Transactions
Details Hidden

Forty Seven, Inc. issued USD Common Stock

Details Hidden

Forty Seven, Inc. raised money in a private placement transaction

Details Hidden

Forty Seven, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onForty Seven, Inc. issued USD Common Stock


Advised onForty Seven, Inc. issued USD Common Stock


Advised onForty Seven, Inc. issued USD Common Stock

Legal Advisor

Advised onForty Seven, Inc. issued USD Common Stock

Legal Advisor

Advised onForty Seven, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner, Palo Alto at Cooley LLP

Key Stats and Financials As of 2018
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Debt
Total Equity
TEVNet Income
Debt TEV
Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Details Hidden

Founder & Vice President Research & Early Development at Forty Seven, Inc.

Details Hidden

Associate Professor at Stanford University

Stanford University Biotechnology | Palo Alto, CA

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

Lonza Group AG Pharmaceuticals | Basel, BS

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Surface Oncology, Inc. Biotechnology - Cambridge, MA

Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

OSE Immunotherapeutics SA Pharmaceuticals - Nantes, PL

OSE Immunotherapeutics SA develops immunotherapy products for late-stage cancers. It provides products include Tedopi, FR104, Effi-7, Effi-Dem and R&D. The company was founded in 2012 and is headquartered in Nantes, France.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Forty Seven, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Forty Seven, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Forty Seven, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15